[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"fc12ec5e-bd90-482d-9d25-a68cd6f10bca","acronym":"LIBRETTO-531","url":"https://clinicaltrials.gov/study/NCT04211337","created_at":"2021-01-18T20:30:33.890Z","updated_at":"2025-02-25T16:52:48.085Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","source_id_and_acronym":"NCT04211337 - LIBRETTO-531","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 291","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"557b19f9-7188-4df8-9db3-bfc502e77692","acronym":"AcceleRET-MTC","url":"https://clinicaltrials.gov/study/NCT04760288","created_at":"2021-02-18T22:55:15.019Z","updated_at":"2024-07-02T16:35:24.361Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","source_id_and_acronym":"NCT04760288 - AcceleRET-MTC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET • CEACAM5","pipe":" | ","alterations":" RET mutation","tags":["RET • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Gavreto (pralsetinib) • Caprelsa (vandetanib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 10/06/2027","primary_completion_date":" 10/06/2027","study_txt":" Completion: 04/12/2035","study_completion_date":" 04/12/2035","last_update_posted":"2024-01-05"},{"id":"1a869e25-9303-4fa9-bd37-0e87d65df9b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00410761","created_at":"2021-01-18T01:26:27.582Z","updated_at":"2024-07-02T16:35:35.053Z","phase":"Phase 3","brief_title":"An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer","source_id_and_acronym":"NCT00410761","lead_sponsor":"Genzyme, a Sanofi Company","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 437","initiation":"Initiation: 11/30/2006","start_date":" 11/30/2006","primary_txt":" Primary completion: 07/31/2009","primary_completion_date":" 07/31/2009","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2023-10-02"},{"id":"73d9dc04-6d86-4317-a893-7c9af61f85f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02268734","created_at":"2021-01-18T10:39:58.225Z","updated_at":"2024-07-02T16:36:23.645Z","phase":"","brief_title":"Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib","source_id_and_acronym":"NCT02268734","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RET mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2021-09-30"},{"id":"f0b947c0-82f0-451e-a0c9-2accffc8242c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01414426","created_at":"2021-01-18T05:49:22.754Z","updated_at":"2024-07-02T16:36:36.031Z","phase":"Phase 2","brief_title":"Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions","source_id_and_acronym":"NCT01414426","lead_sponsor":"University of Chicago","biomarkers":" SOX4","pipe":"","alterations":" ","tags":["SOX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2021-01-14"},{"id":"1640e600-21f8-4f68-9f1c-a3e91566138a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00514046","created_at":"2021-01-18T01:51:05.753Z","updated_at":"2024-07-02T16:36:36.991Z","phase":"Phase 1/2","brief_title":"Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer","source_id_and_acronym":"NCT00514046","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET • CEACAM5","pipe":"","alterations":" ","tags":["RET • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 07/20/2007","start_date":" 07/20/2007","primary_txt":" Primary completion: 12/10/2019","primary_completion_date":" 12/10/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2020-12-22"},{"id":"ed0e327f-1ee8-442a-b623-e2cd401ccbab","acronym":"","url":"https://clinicaltrials.gov/study/NCT01823068","created_at":"2021-01-18T08:06:00.948Z","updated_at":"2025-02-25T15:05:32.537Z","phase":"Phase 2","brief_title":"Vandetanib in Advanced NSCLC With RET Rearrangement","source_id_and_acronym":"NCT01823068","lead_sponsor":"Samsung Medical Center","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 11/03/2014","start_date":" 11/03/2014","primary_txt":" Primary completion: 12/29/2014","primary_completion_date":" 12/29/2014","study_txt":" Completion: 03/16/2018","study_completion_date":" 03/16/2018","last_update_posted":"2020-12-07"},{"id":"83192fa5-da8f-439c-b9cd-52e85a82c7b2","acronym":"Caprelsa104","url":"https://clinicaltrials.gov/study/NCT01945762","created_at":"2021-01-18T08:49:16.888Z","updated_at":"2024-07-02T16:36:39.990Z","phase":"","brief_title":"Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer","source_id_and_acronym":"NCT01945762 - Caprelsa104","lead_sponsor":"Genzyme, a Sanofi Company","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/17/2014","start_date":" 02/17/2014","primary_txt":" Primary completion: 06/18/2020","primary_completion_date":" 06/18/2020","study_txt":" Completion: 06/18/2020","study_completion_date":" 06/18/2020","last_update_posted":"2020-10-19"},{"id":"740d476e-ff93-40d1-91bf-55a32e44d2cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT02015065","created_at":"2021-01-18T09:12:59.306Z","updated_at":"2024-07-02T16:36:47.258Z","phase":"Phase 2","brief_title":"Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT02015065","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/14/2013","start_date":" 12/14/2013","primary_txt":" Primary completion: 05/04/2016","primary_completion_date":" 05/04/2016","study_txt":" Completion: 12/10/2019","study_completion_date":" 12/10/2019","last_update_posted":"2020-03-30"},{"id":"d8dce38f-245f-4356-8d5f-95329d88139f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00613626","created_at":"2021-01-18T02:16:50.222Z","updated_at":"2025-02-25T15:04:00.775Z","phase":"Phase 2","brief_title":"Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT00613626","lead_sponsor":"Hoosier Cancer Research Network","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2020-02-11"},{"id":"7cc55884-aa4a-43e7-b640-e10d463981a4","acronym":"CaprelsaReg","url":"https://clinicaltrials.gov/study/NCT02109250","created_at":"2021-01-18T09:45:06.640Z","updated_at":"2024-07-02T16:37:22.885Z","phase":"","brief_title":"CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice","source_id_and_acronym":"NCT02109250 - CaprelsaReg","lead_sponsor":"Genzyme, a Sanofi Company","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2017-05-02"},{"id":"0accaba4-528c-4e52-b142-4dc378a009d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00358956","created_at":"2021-01-18T01:14:39.527Z","updated_at":"2024-07-02T16:37:26.117Z","phase":"Phase 2","brief_title":"A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer","source_id_and_acronym":"NCT00358956","lead_sponsor":"Genzyme, a Sanofi Company","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 01/01/2008","primary_completion_date":" 01/01/2008","study_txt":" Completion: 05/01/2014","study_completion_date":" 05/01/2014","last_update_posted":"2017-01-30"}]